Target intelligence / Profile preview

LIM domain only protein 3 (LMO3)

Target
LMO3
Molecular classification
Transcription factor, Oncogene, LIM-domain protein, Transcriptional co-factor
01

Overview

LIM domain only protein 3 (LMO3) is a cysteine-rich transcriptional co-factor of the rhombotin family, predominantly expressed in the brain, and functions as a context-dependent transcriptional regulator. LMO3 is implicated in the pathogenesis of several tumors, most notably as an oncogene in neuroblastoma, lung adenocarcinoma, and glioma, where its overexpression correlates with poor prognosis. LMO3 forms complexes with neuronal transcription factors such as HEN2, promotes transcription of cell proliferation regulators, and interacts with the tumor suppressor p53 as a co-repressor, modulating p53-dependent transcriptional responses. While essential for transcriptional regulation processes in neuronal tissue, compensatory mechanisms may exist among LIM-only protein family members; there are currently no approved drugs that specifically target LMO3.

Other names
RBTNL2RBTN3RHOM3RHOM-3DAT1Neuronal-specific transcription factor DAT1Rhombotin-3dopamine associated transcription factor-1LIM domain only 3 (rhombotin-like 2)
02

Mechanism of action

Not directly applicable (no drugs currently, but LMO3 acts as a transcriptional regulator of cell growth genes, influences transcriptional networks in cancer)

03

Biological functions

Transcriptional regulationCell proliferationCell differentiationCell survival
04

Disease associations

Cancer (especially neuroblastoma, lung adenocarcinoma, glioma, adult epithelioid sarcoma, chief cell adenoma)Oncogenic function through modulation of cell proliferation and survival
05

Safety considerations

Potential for oncogenesis when dysregulated/overexpressedNo known direct toxicity, but therapeutic targeting could impact cell proliferation and survival
06

Biomarkers

Overexpression of LMO3 used as poor prognostic marker in neuroblastoma and gliomas

Beyond the preview

Go deeper on LIM domain only protein 3 (LMO3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIM domain only protein 3 (LMO3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call